All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Adjuvant Nivolumab Displays Real-world Benefits in Resected Stage IIIA Melanoma

November 27th 2022

Adjuvant nivolumab produced survival benefits in patients with resected stage IIIA melanoma, where a significant portion of patients were recurrence free at a median follow-up of over 20 months.

Extended Treatment Time With Bevacizumab Does Not Confer PFS Benefit in Ovarian Cancer

November 26th 2022

Increasing the duration of bevacizumab treatment in the frontline setting did not improve progression-free survival for patients with advanced ovarian cancer.

Forging a New Field

November 25th 2022

Almost single-handedly, Jennifer Temel, MD, defined a research field in medicine, creating a new focus on quality of life for patients and survivors.

Halmos Highlights Immunotherapy Treatment Decisions, Emerging ADCs in NSCLC

November 25th 2022

Balazs Halmos, MD, discusses the role of immunotherapy in the frontline setting of NSCLC and the emerging pipeline of antibody-drug conjugates that could affect the treatment paradigm in lung cancer.

Innovative Trajectory Built From Tradition

November 24th 2022

Roy S. Herbst, MD, PhD, helped usher in the age of targeted therapy and immunotherapy in lung cancer, turning an almost hopeless disease into a condition that can be treated and even cured.

PDS0101 Plus Chemoradiation Elicits 100% ORR in High-Risk Locally Advanced Cervical Cancer

November 23rd 2022

PDS0101 given in conjunction with chemoradiation elicited an 100% overall response rate, along with tumor shrinkage greater than 60%, in 9 patients with high-risk, locally advanced cervical cancer, according to results of the phase 2 IMMUNOCERV trial.

Afamitresgene Autoleucel Induces Durable Clinical Response in Advanced Synovial Sarcoma Or Myxoid/Round Cell Liposarcoma

November 23rd 2022

Afamitresgene autoleucel, a novel T-cell therapy, produced good clinical response lasting more than 4 years in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Selpercatinib Approval in RET Fusion+ Solid Tumors Expands Tumor-Agnostic Feasibility

November 23rd 2022

Alexander Drilon, MD, discusses key efficacy and safety data for selpercatinib from LIBRETTO-001, how the FDA approval of selpercatinib affects the current treatment landscape for RET fusion–positive advanced solid tumors, and ongoing research to expand the reach of tumor-agnostic drugs.

FGFR2 Inhibitor RLY-4008 Appears Durable, Tolerable in Cholangiocarcinoma

November 23rd 2022

Suneel Kamath, MD, discusses the current challenges of treating patients with cholangiocarcinoma, the need for more tolerable therapies in this population, and how the significant ORRs and impressive safety profile seen so far with RLY-4008 in the ReFocus trial are indicative of this agent’s efficacy and durability in FGFR2-rearranged cholangiocarcinoma.

Dana-Farber Research Supports FDA Approval of New Therapy for Certain Patients With Ovarian Cancer

November 23rd 2022

Mirvetuximab soravtansine has been granted accelerated approval by the U.S. Food and Drug Administration on November 14 for the treatment of recurrent platinum-resistant high-grade serous ovarian cancer that highly expresses folate receptor alpha.

FDA Extends PDUFA Date for BLA of Omidubicel in Blood Cancers Requiring Transplant

November 23rd 2022

The FDA has extended the Prescription Drug User Fee Act goal date to May 1, 2023, for the biologics license application seeking the approval of omidubicel for patients with blood cancers in need of allogenic hematopoietic stem cell transplant.

Multidisciplinary Approach Leads to Higher Rate of Neoadjuvant Treatment Completion in Pancreatic Cancer

November 23rd 2022

Patients with localized pancreatic adenocarcinoma who received care at a multidisciplinary clinic had significantly higher neoadjuvant therapy completion rates than those treated at a specialty-specific clinic.

Updates from Melanoma Trials Demonstrate New Roles for Adjuvant/Neoadjuvant Treatment

November 23rd 2022

Sapna Patel, MD, reviews several key studies across stages of melanoma and emerging targeted therapies for patients with BRAF mutations.

DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC

November 22nd 2022

The score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–small cell lung cancer treated with single-agent immunotherapy, regardless of performance status.

Investigators Look to Translate Positive Results of Eftilagimod Alpha Combination to NSCLC

November 22nd 2022

Investigators hope to add an additional therapeutic option to the treatment paradigm of non–small cell lung cancer with the development of the novel agent eftilagimod alpha.

Sylvester Scientists Discover a New Therapeutic Target to Treat Deadly Breast Cancer

November 22nd 2022

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that a protein complex that governs gene expression sometimes gets rewired during breast cancer to help estrogen receptor positive tumors resist endocrine therapies and become more aggressive.

Belantamab Mafodotin to Be Withdrawn From US Market for Relapsed/Refractory Myeloma

November 22nd 2022

GlaxoSmithKline plc has initiated the process to withdraw the United States marketing authorization for belantamab mafodotin-blmf for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 4 prior therapies.

European Commission Approves Cemiplimab for Recurrent or Metastatic Cervical Cancer

November 22nd 2022

The European Commission has approved cemiplimab-rwlc monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy.

Frontline Pembrolizumab Plus Chemotherapy Meets OS End Point in HER2-Negative Gastric/GEJ Adenocarcinoma

November 22nd 2022

The combination of pembrolizumab and physician’s choice of chemotherapy produced a statistically significant overall survival benefit vs chemotherapy plus placebo in patients with HER2-negative, locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Building the Optimal Patient Experience Takes Planning and Effort

November 22nd 2022

Ensuring a positive patient experience should be a top priority throughout the entire treatment journey, as higher patient satisfaction can drive improved health outcomes, treatment adherence, and quality of life.